RecruitingPhase 2NCT05595499

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors


Sponsor

Jonsson Comprehensive Cancer Center

Enrollment

88 participants

Start Date

Mar 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.


Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This study is testing whether fisetin — a natural compound found in fruits and vegetables that removes damaged aging cells (called senolytics) — can improve physical function and reduce fatigue in postmenopausal women who have completed treatment for early-stage breast cancer. **You may be eligible if...** - You are a postmenopausal woman (either over 60, or under 60 with confirmed menopause through lab tests or surgical removal of ovaries) - You were diagnosed with stage I–III breast cancer and have completed active treatment **You may NOT be eligible if...** - You received chemotherapy, biological therapy, or immunotherapy in the last 30 days (some exceptions apply for maintenance therapies like tamoxifen or aromatase inhibitors) - You had surgery or radiation in the last 30 days - You have other conditions making participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of blood samples

DRUGFisetin

Given PO

DRUGPlacebo Administration

Given PO

OTHERQuality-of-Life Assessment

Ancillary studies

OTHERQuestionnaire Administration

Ancillary studies


Locations(7)

UCLA Health Cancer Care in Alhambra

Alhambra, California, United States

UCLA Health Beverly Hills Primary & Specialty Care

Beverly Hills, California, United States

UCLA Health Burbank Primary & Specialty Care

Burbank, California, United States

City of Hope Comprehensive Cancer Center

Duarte, California, United States

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States

UCLA Health Primary Care in Marina del Rey

Marina del Rey, California, United States

UCLA Health Primary Care in Pasadena

Pasadena, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05595499


Related Trials